Table 1.
Patient characteristics.
| Characteristics | n | % | Mean (±SD)/Median (Range) |
|---|---|---|---|
| Age (years) | 166 | 100 | 73 (53–80) |
| Baseline PSA-value (ng/mL) | 166 | 100 | 8 (2.1–165) |
| <10 | 100 | 60.2 | 6 (2.1–9.85) |
| 10–20 | 47 | 28.3 | 12.58 (10–20) |
| >20 | 19 | 11.4 | 39 (21.5–165) |
| Post-therapeutic PSA-nadir (ng/mL) | 164 | 100 | 0.1 (0–13.5) |
| Gleason-Score | 166 | 100 | 7 (6–10) |
| <7 | 19 | 11.4 | 6 |
| 7 | 112 | 67,5 | 7 |
| >7 | 35 | 21.1 | 8 (8–10) |
| T stage * | 165 * | 100 | - |
| T1c | 39 | 23.6 | - |
| T2a-b | 53 | 32.1 | - |
| T2c-T3a/b | 71 | 43 | - |
| Tx | 2 | 1.2 | - |
| Risk categories * | 166 | 100 | - |
| Low risk | 5 | 3 | - |
| Intermediate risk | 104 | 62.7 | - |
| High risk | 57 | 34.3 | - |
| Androgen deprivation therapy | 166 | 100 | - |
| Yes | 46 | 27.7 | - |
| No | 120 | 72.2 | - |
| Target volume (EBRT) | 166 | 100 | - |
| Prostate and seminal vesicles | 125 | 75.3 | - |
| Additional irradiation of pelvic lymph nodes | 41 | 24.7 | - |
| Charlson Comorbidity Index | 165 | 100 | 4 (1–9) |
* For defining risk categories, classification according to NCCN was applied. Thus, the worst/highest parameter was leading in defining the underlying risk group. EBRT: External Beam Radiation Therapy; NCCN: National Comprehensive Cancer Center.